IntelGenx Technologies Corp (IGXT)

[evenkeel]

Next month we should get a readout on the early patients in the Alzheimers study. It is still blinded and will probably focus only on safety, but it's possible they say something about trends in the condition of symptoms. So if the readout says a few patients have had a noticeable improvement, then that could be a catalyst.

The Rizaport filing puts the FDA on a six month schedule to approval, assuming this time it gets the OK. They said in the CC that partners are ready to launch shortly after that. That should also be about the same time the final readout comes on the Alzheimers study. Those usually take over a month to compile once finished, but once they say the study has been completed, we will know more.